New agents in the treatment of acute myeloid leukemia: A snapshot of signal transduction modulation

Clinical Advances in Hematology and Oncology

Volumn 3, Issue 4, 2005, Pages

  Bao, Ting ^a   Smith, B Douglas ^b   Karp, Judith E ^b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

Acute myeloid leukemia; Farnesyl transferase inhibitors; FLT3; PI3K Akt pathway; Signal transduction pathways; VEGF

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CEP 701; CYTOTOXIC AGENT; FLT3 LIGAND; GROWTH FACTOR; LONAFARNIB; MIDOSTAURIN; MITOGEN ACTIVATED PROTEIN KINASE; NEW DRUG; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; SEMAXANIB; SORAFENIB; SUNITINIB; TIPIFARNIB; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VATALANIB;

ACUTE GRANULOCYTIC LEUKEMIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATAXIA; BRONCHOPNEUMONIA; CELL SURVIVAL; CLINICAL TRIAL; CONFUSION; DIARRHEA; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG TARGETING; DYSARTHRIA; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERBILIRUBINEMIA; MALIGNANT NEOPLASTIC DISEASE; MUSCLE WEAKNESS; NEUROTOXICITY; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE;

ACUTE DISEASE; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; FARNESYLTRANSTRANSFERASE; FMS-LIKE TYROSINE KINASE 3; FORECASTING; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, MYELOID; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; MULTICENTER STUDIES; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 25844453430     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (106)

1. Buchner T, Hiddemann W, Wormann B, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood. 1999;93:4116-4124.
2. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998;339:1649-1656.
3. Geller RB, Burke PJ, Karp JE, et al. A two-step timed sequential treatment for acute myelocytic leukemia. Blood. 1989;74:1499-1506.
4. Karp JE, Smith MA. The molecular pathogenesis of treatment-induced (secondary) leukemias: foundations for treatment and prevention. Semin Oncol. 1997;24:103-113.
5. Lancet JE, Karp JE. Farnesyl transferase inhibitors in myeloid malignancies. Blood Rev. 2003;17:123-129.
6. Green MR. Targeting targeted therapy. N Engl J Med. 2004;350:2191-2193.
7. Ravandi F, Kantarjian H, Giles F, Cortes J. New agents in acute myeloid leukemia and other myeloid disorders. Cancer. 2004;100:441-454.
8. Ravandi F, Talpaz M, Estrov Z. Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies. Clin Cancer Res. 2003;9:535-550.
9. Scheijen B, Griffin JD. Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. Oncogene. 2002;21:3314-3333.
10. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100:1532-1542.
11. Brown P, Meshinchi S, Levis M, et al. Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition. Blood. 2004;104:1841-1849.
12. Levis M, Allebach J, Tse KF, et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood. 2002;99:3885-3891.
13. Smith BD, Levis M, Beran M, et al. Single agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood. 2004;103:3669-3776.
14. Levis M, Small D. Novel FLT3 tyrosine kinase inhibitors. Expert Opin Investig Drugs. 2003;12:1951-1962.
15. Levis M, Pham R, Smith BD, Small D. In vitro studies of a FM inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood. 2004;104:1145-1150.
16. Voutsadakis IA. FLT3 in acute myelogenous leukemia: biology, prognosis, and therapeutic implications. Med Oncol. 2003;20:311-323.
17. Stone RM, De Angelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005;105(1):54-60.
18. Griswold IJ, Shen LJ, La Rosee P, et al. Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. Blood. 2004;104:2912-2918.
19. De Angelo DJ, Stone RM, Bruner RJ, et al. Phase I clinical results with MLN518, a novel FLT3 antagonist: tolerability, pharmacokinetics, and pharmacodynamics. Blood. 2003;102:65A-66A.
20. De Angelo DJ, Stone RM, Druker B, et al. Phase II evaluation of the tyrosine kinase inhibitor MLN518 in patients with acute myeloid leukemia (AML) bearing a FLT3 internal tandem duplication (ITD) mutation [abstract]. Blood. 2004;104:496a. Abstract 1792.
21. Gitay-Goren H, Soker S, Vlodavsky I, Neufeld G. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J Biol Chem. 1992;267:6093-6098.
22. Kennedy M, Beug H, Wagner EF, Keller G. Factor-dependent erythroid cell lines derived from mice transplanted with hematopoietic cells expressing the v-src oncogene. Blood. 1992;79:180-190.
23. Ziegler BL, Kanz L. Expansion of stem and progenitor cells. Curr Opin Hematol. 1998;5:434-440.
24. Bikfalvi A, Han ZC. Angiogenic factors are hematopoietic growth factors and vice versa. Leukemia. 1994;8:523-529.
25. Bussolino F, Colotta F, Bocchietto E, Guglielmetti A, Mantovani A. Recent developments in the cell biology of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor: activities on endothelial cells. Int J Clin Lab Res. 1993;23:8-12.
26. Fiedler W, Graeven U, Ergun S, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood. 1997;89:1870-1875.
27. Gabrilove JL, White K, Rahman Z, Wilson EL. Stem cell factor and basic fibroblast growth factor are synergistic in augmenting committed myeloid progenitor cell growth. Blood. 1994;83:907-910.
28. Aguayo A, Estey E, Kantarjian H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. 1999;94:3717-3721.
29. Bellamy WT, Richter L, Sirjani D, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood. 2001;97:1427-1434.
30. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood. 2000;95:309-313.
31. Padro T, Ruiz S, Bieker R, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. 2000;95:2637-2644.
32. Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 1998;92:4150-4166.
33. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
34. Woiciechowsky A, Regn S, Kolb HJ, Roskrow M. Leukemic dendritic cells generated in the presence of FLT3 ligand have the capacity to stimulate an autologous leukemia-specific cytotoxic T cell response from patients with acute myeloid leukemia. Leukemia. 2001;15:246-255.
35. Narita M, Takahashi M, Liu A, et al. Leukemia blast-induced T-cell anergy demonstrated by leukemia-derived dendritic cells in acute myelogenous leukemia. Exp Hematol. 2001;29:709-719.
36. Karp JE, Gojo I, Pili R, et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-D-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res. 2004;10:3577-3585.
37. Giles FJ, Stopeck AT, Silverman LR, et al. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood. 2003;102:795-801.
38. Morgan B, Drevs J, Steward WP, et al. Defining the biologically active dose for PTK787/ZK222584 (PTK/ZK), a vascular endothelial growth factor (VEGF) receptor inhibitor, based on the assessment of two biomarkers [dynamic contrast enhanced magnetic resonance imaging (DCE-MRI), plasma VEGF] in two phase I studies. Eur J Cancer. 2002;38:S75.
39. Lin B, Podar K, Gupta D, et al. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2002;62:5019-5026.
40. Goldbrunner R, Bendszus M, Wood J, et al. PTK787/ZK222584, an inhibitor of VEGF receptor tyrosine kinases, decreases glioma growth and vascularization. J Vasc Res. 2004;41:96.
41. Sivakumar B, Harry LE, Paleolog EM. Modulating angiogenesis: more vs less. JAMA. 2004;292:972-977.
42. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327-337.
43. Hurwitz HI, Eckhardt SG, Holden SN, et al. A phase I study of ZD6474, an oral VEGF receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res. 2001;7:3654S.
44. Traxler P, Allegrini PR, Brandt R, et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 2004;64:4931-4941.
45. Herrera R, Sebolt-Leopold JS. Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention. Trends Mol Med. 2002;8:S27-S31.
46. Ashar HR, James L, Gray K, et al. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem. 2000;275:30451-30457.
47. End DW. Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway. Invest New Drugs. 1999;17:241-258.
48. Reiss Y, Goldstein JL, Seabra MC, Casey PJ, Brown MS. Inhibition of purified p21 ras farnesyl: protein transferase by Cys-AAX tetrapeptides. Cell. 1990;62:81-88.
49. Reuter CW, Morgan MA, Bergmann L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood. 2000;96:1655-1669.
50. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst. 2001;93:1062-1074.
51. Du W, Lebowitz PF, Prendergast GC. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol Cell Biol. 1999;19:1831-1840.
52. Gibbs BS, Zahn TJ, Mu Y, Sebolt-Leopold JS, Gibbs RA. Novel farnesyl and geranylgeraniol analogues: a potential new class of anticancer agents directed against protein prenylation. J Med Chem. 1999;42:3800-3808.
53. James GL, Brown MS, Goldstein JL. Assays for inhibitors of CAAX farnesyltransferase in vitro and in intact cells. Methods Enzymol. 1995;255:38-46.:38-46.
54. Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol. 1999;17:3631-3652.
55. Chin L, Tam A. Pomerantz J, et al. Essential role for oncogenic Ras in tumour maintenance. Nature. 1999;400:468-472.
56. Feldkamp MM, Lau N, Guha A. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. Oncogene. 1999;18:7514-7526.
57. Peters DG, Hoover RR, Gerlach MJ, et al. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood. 2001;97:1404-1412.
58. Reichert A, Heisterkamp N, Daley GQ, Groffen J. Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336. Blood. 2001;97:1399-1403.
59. Jiang K, Coppola D, Crespo NC, et al. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol. 2000;20:139-148.
60. Cortes J, Kurzrock R, O'Brien SM, et al. Phase I study of a farnesyl transferase inhibitor (FTI), BMS-214662, in patients with refractory or relapsed acute leukemias [abstract]. Blood. 2001;98:594A.
61. Adjei AA, Erlichman C, Davis JN, et al. A phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res. 2000;60:1871-1877.
62. Cortes J. Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Clin Lymphoma. 2003;4:S30-S35.
63. Cortes J, Albitar M, Thomas D, et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood. 2003;101:1692-1697.
64. Gotlib J, Loh M, Lancet JE, et al. Phase I/II study of tipifarnib (ZARNESTRA (TM), farnesyltransferase inhibitor [FTI] R115777) in patients with myeloproliferative disorders (MPDs): interim results. Blood. 2003;102:921A.
65. Kurzrock R, Cortes J, Ryback ME, et al. Phase II study of R115777, a farnesyltransferase inhibitor, in myelodysplastic syndrome. Blood. 2001;98:848A.
66. Kurzrock R, Sebti SM, Kantarjian HM, et al. Phase I study of a farnesyl transferase inhibitor, R115777, in patients with myelodysplastic syndrome. Blood. 2001;98:623A.
67. Lancet JE, Gojo I, Gotlib J, et al. Tipifarnib (Zarnestra(TM)) in previously untreated poor-risk AML and MDS: interim results of a phase 2 trial. Blood. 2003;102:176A.
68. Lancet JE, Gotlib J, and et al. Tipifarnib (ZarnestraTM) in previously untreated poor-risk AML of the elderly: updated results of a multicenter phase 2 trial. [abstract]. Blood. 2004;104:249a. Abstract 874.
69. Mesa RA, Tefferi A, Gray L, Schroeder G, Kaufmann SH. The farnesyltransferase inhibitor, R115777, has significant in vitro activity in myelofibrosis with myeloid metaplasia. Blood. 2001; 98:469A-470A.
70. Mesa RA, Camoriano JK, Geyer SM, et al. A phase 2 consortium (P2C) trial of r115777 (Zarnestra) in myelofibrosis with myeloid metaplasia: Interim analysis of 18 patients. Blood. 2003;102:922A.
71. Ryan DP, Eder JP, Puchlaski T, et al. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors. Clin Cancer Res. 2004;10:2222-2230.
72. Tabernero J, Albanell J, Rojo F, et al. A phase I pharmacokinetic (PK) and serial tumor and PBMC pharmacodynamic (PD) study of weekly 24-hour (h) infusion BMS-214662, a farnesyltransferase (FT) inhibitor, in patients (p) with advanced solid tumors. Clin Cancer Res. 2001;7:3775S.
73. Winquist E, Moore MJ, Chi K, et al. A phase II study of a farnesyl transferase inhibitor (SCH 66336) in patients with unresectable or metastatic transitional cell carcinoma of the urothelial tract failing prior chemotherapy. [abstract]. Proc Am Soc Clin Oncol. 2001.
74. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 2001;97:3361-3369.
75. Harousseau JL, Reiffers J, Lowenberg B, et al. Zarnestra (TM) (R115777) in patients with relapsed and refractory acute myelogenous leukemia (AML): results of a multicenter phase 2 study. Blood. 2003;102:176A.
76. Feldman EJ, Cortes J, Holyoake TL, et al. Continuous oral lonafarnib (Sarasar) for the treatment of patients with myelodysplastic syndrome [abstract]. Blood. 2003;102:421a. Abstract 1531.
77. Cortes J, HolyoakeTL, Silver RT, et al. Continuous oral lonafarnib (SarasarTM) for the treatment of patients with advanced hematologic malignancies: a phase II study [abstract]. Blood. 2002;100:793a.
78. Sebti SM, Der CJ. Opinion: searching for the elusive targets of farnesyltransferase inhibitors. Nat Rev Cancer. 2003;3:945-951.
79. Raponi M, Belly RT, Karp JE, et al. Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia. Bmc Cancer. 2004;4:56.
80. Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ. Increasing complexity of Ras signaling. Oncogene. 1998;17:1395-1413.
81. Chong H, Vikis HG, Guan KL. Mechanisms of regulating the Raf kinase family. Cell Signal. 2003;15:463-469.
82. Mercer KE, Pritchard CA. Raf proteins and cancer: b-raf is identified as a mutational target. Biochim Biophys Acta-Rev Cancer. 2003;1653:25-40.
83. Dasgupta P, Sun JZ, Wang S, et al. Disruption of the Rb-Raf-1 interaction inhibits tumor growth and angiogenesis. Mol Cell Biol. 2004;24:9527-9541.
84. Crump M, Leber B, Buckstein R, et al. A randomized phase I clinical and biologic study of two schedules of the raf-kinase inhibitor BAY 43-9006 in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): A NCI Canada Clinical Trials Group study. Blood. 2002;100:267B.
85. Sebolt-Leopold JS, Dudley DT, Herrera R, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med. 1999;5:810-816.
86. Mansour SJ, Matten WT, Hermann AS, et al. Transformation of mammalian-cells by constitutively active MAP kinase kinase. Science. 1994;265:966-970.
87. Kim SC, Hahn JS, Min YH, et al. Constitutive activation of extracellular signal-regulated kinase in human acute leukemias: combined role of activation of MEK, hyperexpression of extracellular signal-regulated kinase, and downregulation of a phosphatase, PAC1. Blood. 1999;93:3893-3899.
88. Meng XW, Chandra J, Loegering D, et al. Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro. J Biol Chem. 2003;278:47326-47339.
89. Milella M, Kornblau SM, Estrov Z, et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest. 2001;108:851-859.
90. Towatari M, Iida H, Tanimoto M, et al. Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells. Leukemia. 1997;11:479-484.
91. Chang F, Lee JT, Navolanic PM, et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia. 2003;17:590-603.
92. Jucker M, Sudel K, Horn S, et al. Expression of a mutated form of the p85 alpha regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin's lymphoma-derived cell line (CO). Leukemia. 2002;16:894-901.
93. Birkenkamp KU, Geugien M, Schepers H, et al. Constitutive NF-kappa B DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway. Leukemia. 2004;18:103-112.
94. Min YH, Eom JI, Cheong JW, et al. Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia. 2003;17:995-997.
95. Hsu JH, Shi YJ, Krajewski S, et al. The Akt kinase is activated in multiple myeloma tumor cells. Blood. 2001;98:2853-2855.
96. Nakatani K, Thompson DA, Barthel A, et al. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem. 1999;274:21528-21532.
97. Brognard J, Clark AS, Ni YC, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001;61:3986-3997.
98. Marley SB, Lewis JL, Schneider H, Rudd CE, Gordon MY. Phosphatidylinositol-3 kinase inhibitors reproduce the selective antiproliferative effects of imatinib on chronic myeloid leukaemia progenitor cells. Br J Haematol. 2004;125:500-511.
99. Zhao S, Konopleva M, Cabreira-Hansen M, et al. Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia. 2004;18:267-275.
100. Martelli AM, Tazzari PL, Tabellini G, et al. A new selective Akt pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells. Leukemia. 2003;17:1794-1805.
101. Liu XS, Shi Y, Han EKH, et al. Downregulation of Akt1 inhibits anchorage-independent cell growth and induces apoptosis in cancer cells. Neoplasia. 2001;3:278-286.
102. Estey EH, Thall PF. New designs for phase 2 clinical trials. Blood. 2003;102:442-448.
103. Estey EH, Fisher T, Giles F, et al. A randomized phase II trial of the tyrosine kinase inhibitor PKC412 in patients (pts) with acute myeloid leukemia (AML)/high-risk myelodysplastic syndromes (MDS) characterized by wild-type (WT) or mutated FLT3. Blood. 2003;102:614A-615A.
104. Fiedler W, Mesters R, Tinnefeld H, et al. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood. 2003;102:2763-2767.
105. O'Farrell AM, Foran JM, Fiedler W, et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res. 2003;9:5465-5476.
106. Beebe JS, Jani JP, Knauth E, et al. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res. 2003;63:7301-7309.